【摘要】 抗IgE单克隆抗体目前已被批准用于治疗哮喘和慢性荨麻疹，同时抗IgE单克隆抗体联合变应原特异性免疫治疗（AIT）作为过敏性疾病的辅助治疗已引起普遍关注。研究表明，在AIT治疗中或治疗前添加抗IgE单克隆抗体可显著减少AIT不良反应的发生频率和严重程度，明显改善症状评分，缩短达到维持剂量所需的时间。目前仍需要更大规模的高质量对照试验更好地识别抗IgE单克隆抗体联合AIT的获益人群，以及治疗最佳剂量和持续时间，并评估长期效益、进行成本-效益分析。本文就抗IgE单克隆抗体在AIT中作为辅助治疗的应用进展进行综述。更多还原

【Abstract】 Anti-IgE monoclonal antibodies have been approved for the treatment of asthma and chronic urticaria,and anti-IgE monoclonal antibodies combined with allergen immunotherapy(AIT) have attracted widespread attention as an adjunctive therapy for allergic diseases. Studies have shown that the addition of anti-IgE monoclonal antibodies during or before AIT treatment significantly reduces the frequency and severity of AIT adverse reactions, significantly improves the symptom scores, and shortens the time required to achieve maintenance doses. Larger, high-quality, placebo-controlled trials are still needed to better identify the beneficiaries of anti-IgE monoclonal antibodies in conjunction with AIT, as well as the optimal dose and duration of treatment, and to assess long-term benefits and conduct cost-benefit analysis. This article reviews the application of anti-IgE monoclonal antibodies as adjunctive therapy in AIT.更多还原